AnaptysBio Inc (NASDAQ:ANAB)
| 16.92 Delayed Data As of 3:59pm ET |  -0.23 / -1.34%Today’s Change | 16.51 Today|||52-Week Range 32.44 | -45.40% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $517.6M |
Company Description
AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
Contact Information
AnaptysBio, Inc. 10770 Wateridge Circle San Diego California 92121-5801 |
Employees
Shareholders
| Other institutional | 80.90% |
| Individual stakeholders | 47.13% |
| Mutual fund holders | 23.58% |
Top Executives
| Daniel R. Faga | President, Chief Executive Officer & Director |
| Dennis M. Mulroy | Chief Financial Officer |
| Paul F. Lizzul | Chief Medical Officer |
| David McKeon | Vice President & Controller |
| Martin Dahl | Senior Vice President-Research |
